# SyntheX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synthex

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.synthexlabs.com
- Total disclosed funding: $11M
- Latest round: Seed (Dec 29, 2023)
- Investors on record: 5

## About

SyntheX, Inc. is a biotech firm focused on innovative drug discovery solutions, utilizing its ToR FLEx platform to overcome challenges in traditional pharmacological approaches and reach previously inaccessible protein targets.SyntheX, Inc. specializes in advanced drug discovery solutions, notably through its ToR FLEx platform. Founded in 2016 and headquartered in San Francisco, US, the company has completed three deals, with the most recent funding round occurring on April 20, 2017. The firm successfully raised USD 6.2 million in Seed funding, led by Morgan Noble and supported by 8VC, Oriza Ventures, and SOSV. The company was co-founded by Charly Chahwan and Maria Soloveychik, who currently serves as CEO.SyntheX specializes in advanced drug discovery solutions, primarily through its innovative ToR FLEx platform. This technology enables the engineering of cells to conduct functional selection of compounds that can modulate challenging protein targets, thereby unveiling novel mechanisms of action. The company's core offerings focus on overcoming limitations in traditional pharmacological approaches, particularly for high-potential drug targets that are often deemed inaccessible. End users include pharmaceutical companies and research institutions looking to expand their drug discovery capabilities into previously unreachable areas of the proteome. SyntheX's products are positioned within global markets, notably targeting regions with advanced biotech industries, including North America, Europe, and select parts of Asia.SyntheX's revenue model encompasses partnerships and collaborations with pharmaceutical and biotech firms, facilitating the discovery of new drug compounds. The company engages in B2B transactions, offering access to its ToR FLEx platform to external partners who seek to develop targeted therapies. Through these collaborations, SyntheX may implement contractual agreements that outline specific milestones and deliverables tied to the drug discovery process. Revenue may be generated through licensing deals or by providing access to proprietary technologies, with pricing structures potentially reflecting the complexity and scope of the projects undertaken. The company’s focus on generating a robust oncology pipeline indicates a strategic approach to attract clients seeking cutting-edge solutions in drug development.In April 2017, SyntheX, Inc. raised USD 6.2 million in Seed funding, which will support its ongoing development of the ToR FLEx platform and advance its drug discovery initiatives. The company plans to design and launch new products aimed at enhancing its capabilities in drug discovery, although specific release dates have not been disclosed. Additionally, SyntheX is targeting expansion into new markets, particularly in Europe and Asia, to establish partnerships with local pharmaceutical companies and research institutions, enhancing its global footprint in the biotech industry.

## Funding rounds

- Seed, Dec 29, 2023, $5.2M — SOSV
- Seed, Apr 20, 2017, $6.2M — SOSV, Morgan Noble, 8VC, Oriza Ventures
- Seed, Feb 17, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Morgan Noble (https://capitalatlas.ai/funds/morgan-noble) — Seed
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed
- Oriza Ventures (https://capitalatlas.ai/funds/oriza-ventures) — Seed